Clinical Study

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma

Figure 1

Month of diagnosis of patient cohorts. Time line of patient accrual to BEV and No-BEV groups as a function of month of GBM diagnosis. Dot plot indicates month of diagnosis. Using 1/1/2005 as Time 0, there is a statistically but not clinically significant difference in dates of diagnosis.
602812.fig.001